Study on low-grade galena-barite ore beneficiation in Khuzdar, Balochistan, Pakistan

Purpose. Galena and barite are the principal minerals of lead and barium respectively. Both minerals are used extensively in industries because of their distinct properties. In complex poly metallic ores, it is always desirable to produce separate mineral concentrates for subsequent metal extraction. Separation of two or more minerals from complex low-grade multi-metallic ore into commercial grade concentrates requires suitable process. Methods. This research work is centered on development a suitable process for the beneficiation of a low-grade galena-barite ore originating from Khuzdar region (Balochistan Province, Pakistan). Findings. The low-grade ore assaying 39.90% Pb and 24.64% BaSO4 was beneficiated on bench-scale by sequential froth flotation process to recover valuable galena and barite concentrates. The important variables of froth flotation process such as feed size, pulp pH, pulp density, impeller speed, type and quantities of flotation reagents, pulp conditioning time and froth collecting time were optimized to achieve maximum recovery and grade of both concentrates. The rougher galena and barite concentrates were re-ground separately and subjected to one cleaning flotation to obtain better grade final concentrates of respective minerals. Originality. A process flow-sheet was designed in the light of this study. Practical implications. Froth flotation experiments showed that a galena concentrate containing 77.38% Pb with recovery of 90.64% and a barite concentrate assaying 90.23% BaSO4 with recovery of 80.16% could be recovered from this ore. Both the concentrates fall in the category of metallurgical and chemical grades and are suitable for industrial applications.Мета. Підвищення якості низькосортної галеніт-баритової руди, знайденої в Хуздарском районі провінції Белуджистан (Пакистан), до концентрату металургійного якості, що містить більше 70% Pb, із використанням методу пінної флотації. Методика. Масова проба галеніт-баритової руди вагою близько 100 кг була відібрана з шахти Мал-Хор на північному заході від Хуздару та доставлена в лабораторію переробки мінералів MPRC, PCSIR Lahore для проведення досліджень. Зразок підданий первинному подрібненню із використанням щокової дробарки з наступним вторинним подрібненням із використанням валкової дробарки. Зразок до і після флотації піддавався комплексному хімічному і рентгеноструктурному аналізу (XRD). Флотаційні випробування проводилися на лабораторній флотаційній машині D-12. Після визначення оптимального помелу були проведені випробування для оптимізації щільності пульпи, рН пульпи, швидкості перемішування, кількості доданих реагентів, часу флотації й часу кондиціонування. Результати. Встановлено, що вміст свинцю та барію в поліметалічній руді є достатнім для промислового використання. Отримано оптимальну ступінь подрібнення і відновлення при розмірі подачі 80% мінус 200 меш. Виявлено, що збільшення щільності пульпи дещо знижується при збільшенні В/Т з 20 до 35%, але відновлення збільшується, а максимальне відновлення досягнуто при 30%. При використанні для коригування рН пульпи етілксантата калію, а потім бариту з олеатом натрію, виявлено, що при постійних умовах розміру часток і співвідношення твердої речовини та рідини максимально повторне покриття галену досягається при рН 8.5 і бариту при рН 10.0. Було відзначено, що невелика зміна pH значно змінила ступінь і відновлення. Розкрито вплив швидкості перемішування робочого колеса й відзначено, що оптимальною швидкістю на грубій стадії є швидкість 1100 об/хв, а на стадії очищення – 1000 об/хв. Доведено, що методом пінної флотації з даної руди можна отримати концентрат галеніту із вмістом 77.38% Pb і ступенем відновлення 90.64%, а також концентрат бариту із вмістом 90.23% BaSO4 і ступенем відновлення 80.16%. Наукова новизна. Встановлено характер впливу специфічних речовин, що поліпшують показники про-процесу флотації, які сприяють якісному відділенню цінних компонентів руди від порожніх домішок. Практична значимість. Розроблено принципову схему процесу збагачення галеніт-баритової руди на основі пінної флотації в замкнутому циклі. Отримані концентрати галеніту й бариту відповідають необхідним металургійним і хімічним стандартам та можуть знайти промислове застосування.Цель. Повышение качества низкосортной галенит-баритовой руды, найденной в Хуздарском районе провинции Белуджистан (Пакистан), до концентрата металлургического качества, содержащего более 70% Pb, с использованием метода пенной флотации. Методика. Массовая проба галенит-баритовой руды весом около 100 кг была отобрана из шахты Мал-Хор к северо-западу от Хуздара и доставлена в лабораторию переработки минералов MPRC, PCSIR Lahore для проведения исследований. Образец подвергнут первичному дроблению с использованием щековой дробилки, с последующим вторичным дроблением с использованием валковой дробилки. Образец до и после флотации подвергался комплексному химическому и рентгеноструктурному анализу (XRD). Флотационные испытания проводились на лабораторной флотационной машине D-12. После определения оптимального помола были проведены испытания для оптимизации плотности пульпы, рН пульпы, скорости перемешивания, количества добавленных реагентов, времени флотации и времени кондиционирования. Результаты. Установлено, что содержание свинца и бария в полиметаллической руде является достаточным для промышленного использования. Получена оптимальная степень измельчения и восстановления при размере подачи 80% минус 200 меш. Выявлено, что увеличение плотности пульпы несколько снижается при увеличении В/Т с 20 до 35%, но восстановление увеличилось, а максимальное восстановление достигнуто при 30%. При использовании для корректировки рН пульпы этилксантата калия, а затем барита с олеатом натрия, обнаружено, что при постоянных условиях размера частиц и соотношения твердого вещества и жидкости максимальное повторное покрытие галена достигается при рН 8.5 и барита при рН 10.0. Было отмечено, что небольшое изменение pH значительно изменило степень и восстановление. Раскрыто влияние скорости перемешивания рабочего колеса и отмечено, что оптимальной скоростью на грубой стадии является скорость 1100 об/мин, а на стадии очистки – 1000 об/мин. Доказано, что методом пенной флотации из данной руды можно получить концентрат галенита с содержанием 77.38% Pb и степенью восстановления 90.64%, а также концентрат барита с содержанием 90.23% BaSO4 и степенью восстановления 80.16%. Научная новизна. Установлен характер влияния специфических веществ, улучшающих показатели процесса флотации, что способствовало качественному отделению ценных компонентов руды от пустых примесей. Практическая значимость. Разработана принципиальная схема процесса обогащения галенит-баритовой руды на основе пенной флотации в замкнутом цикле. Полученные концентраты галенита и барита соответствуют металлургическим и химическим стандартам и могут найти промышленное применение.The authors are grateful to Associate Professor, Dr. Zulifqar Ali, Department of Mining Engineering, University of Engineering and Technology (UET), Lahore for his valuable support/ cooperation in X-ray diffraction (XRD) analysis and mineralogical evaluation of ore

Effects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study

Background Early death after cancer surgery is higher in low-income and middle-income countries (LMICs) compared with in high-income countries, yet the impact of facility characteristics on early postoperative outcomes is unknown. The aim of this study was to examine the association between hospital infrastructure, resource availability, and processes on early outcomes after cancer surgery worldwide.Methods A multimethods analysis was performed as part of the GlobalSurg 3 study-a multicentre, international, prospective cohort study of patients who had surgery for breast, colorectal, or gastric cancer. The primary outcomes were 30-day mortality and 30-day major complication rates. Potentially beneficial hospital facilities were identified by variable selection to select those associated with 30-day mortality. Adjusted outcomes were determined using generalised estimating equations to account for patient characteristics and country-income group, with population stratification by hospital.Findings Between April 1, 2018, and April 23, 2019, facility-level data were collected for 9685 patients across 238 hospitals in 66 countries (91 hospitals in 20 high-income countries; 57 hospitals in 19 upper-middle-income countries; and 90 hospitals in 27 low-income to lower-middle-income countries). The availability of five hospital facilities was inversely associated with mortality: ultrasound, CT scanner, critical care unit, opioid analgesia, and oncologist. After adjustment for case-mix and country income group, hospitals with three or fewer of these facilities (62 hospitals, 1294 patients) had higher mortality compared with those with four or five (adjusted odds ratio [OR] 3.85 [95% CI 2.58-5.75]; p<0.0001), with excess mortality predominantly explained by a limited capacity to rescue following the development of major complications (63.0% vs 82.7%; OR 0.35 [0.23-0.53]; p<0.0001). Across LMICs, improvements in hospital facilities would prevent one to three deaths for every 100 patients undergoing surgery for cancer.Interpretation Hospitals with higher levels of infrastructure and resources have better outcomes after cancer surgery, independent of country income. Without urgent strengthening of hospital infrastructure and resources, the reductions in cancer-associated mortality associated with improved access will not be realised

Twelve-month observational study of children with cancer in 41 countries during the COVID-19 pandemic

Introduction Childhood cancer is a leading cause of death. It is unclear whether the COVID-19 pandemic has impacted childhood cancer mortality. In this study, we aimed to establish all-cause mortality rates for childhood cancers during the COVID-19 pandemic and determine the factors associated with mortality. Methods Prospective cohort study in 109 institutions in 41 countries. Inclusion criteria: children <18 years who were newly diagnosed with or undergoing active treatment for acute lymphoblastic leukaemia, non-Hodgkin's lymphoma, Hodgkin lymphoma, retinoblastoma, Wilms tumour, glioma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, medulloblastoma and neuroblastoma. Of 2327 cases, 2118 patients were included in the study. The primary outcome measure was all-cause mortality at 30 days, 90 days and 12 months. Results All-cause mortality was 3.4% (n=71/2084) at 30-day follow-up, 5.7% (n=113/1969) at 90-day follow-up and 13.0% (n=206/1581) at 12-month follow-up. The median time from diagnosis to multidisciplinary team (MDT) plan was longest in low-income countries (7 days, IQR 3-11). Multivariable analysis revealed several factors associated with 12-month mortality, including low-income (OR 6.99 (95% CI 2.49 to 19.68); p<0.001), lower middle income (OR 3.32 (95% CI 1.96 to 5.61); p<0.001) and upper middle income (OR 3.49 (95% CI 2.02 to 6.03); p<0.001) country status and chemotherapy (OR 0.55 (95% CI 0.36 to 0.86); p=0.008) and immunotherapy (OR 0.27 (95% CI 0.08 to 0.91); p=0.035) within 30 days from MDT plan. Multivariable analysis revealed laboratory-confirmed SARS-CoV-2 infection (OR 5.33 (95% CI 1.19 to 23.84); p=0.029) was associated with 30-day mortality. Conclusions Children with cancer are more likely to die within 30 days if infected with SARS-CoV-2. However, timely treatment reduced odds of death. This report provides crucial information to balance the benefits of providing anticancer therapy against the risks of SARS-CoV-2 infection in children with cancer

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BACKGROUND Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. METHODS The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56 604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model-a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates-with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality-which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds. FINDINGS The leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2-100·0) per 100 000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1-290·7] per 100 000 population) and Latin America and the Caribbean (195·4 deaths [182·1-211·4] per 100 000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4-48·8] per 100 000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3-37·2] per 100 000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7-9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles. INTERPRETATION Long-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere. FUNDING Bill & Melinda Gates Foundation

In Vivo and in Vitro Monitoring of Amyloid Aggregation via BSA@FGQDs Multimodal Probe

Early detection of peptide aggregate intermediates is quite challenging because of their variable and complex nature as well as due to lack of reliable sensors for diagnosis. Herein, we report the detection of monomers and oligomers using specified fluorescence and a magnetic resonance imaging (MRI) multimodal probe based on bovine-serum-albumin-capped fluorine functionalized graphene quantum dots (BSA@FGQDs). This probe enables in vitro fluorescence-based monitoring of human islet amyloid polypeptide (hIAPP), insulin, and amyloid β (1-42) (Aβ 42 ) monomers and oligomers during the fibrillogenesis dynamic. Up to 90% fluorescence quenching of BSA@FGQDs probe upon addition of amyloid monomers/oligomers was observed due to static quenching and nonradiative energy transfer. Moreover, the BSA@FGQDs probe shows 10 times higher signals in detecting amyloid intermediates and fibrils than that of conventional thioflavin dye. A negative Î"G° value (-36.21 kJ/mol) indicates spontaneous interaction of probe with the peptide. These interactions are hydrogen bonding and hydrophobic as proved by thermodynamic parameters. Visual binding clues of BSA@FGQDs with different morphological states of amyloid protein was achieved through electron microscopy. Furthermore, intravenous and intracranial injection of BSA@FGQDs probe in Alzheimer model mice brain enabled in vivo detection of amyloid plaques in live mice brain by 19 F MRI through contrast enhancement. Our proposed probe not only effectively monitors in vitro fibrillation kinetics of number of amyloid proteins with higher sensitivity and specificity than thioflavin dye, but also, the presence of a 19 F center makes BSA@FGQDs an effective probe as a noninvasive and nonradiative in vivo detection probe for amyloid plaques

Porous Eleocharis@MnPE Layered Hybrid for Synergistic Adsorption and Catalytic Biodegradation of Toxic Azo Dyes from Industrial Wastewater

The effective treatment of industrial wastewater to protect freshwater reserves for the survival of life is a primary focus of current research. Herein, a multicomponent Eleocharis-manganese peroxidase enzyme (Eleocharis@MnPE) layered hybrid with high surface area (1200 m 2 /m 3 ), with a strong synergistic adsorption and catalytic biodegradation (SACB), has been developed through a facile method. A combination of outer porous (Eleocharis) and inner catalytically active (MnPE) components of the hybrid resulted in highly efficient SACB system, evidenced by high removal rate of 15 kg m -3 day -1 (100%) and complete degradation of toxic Orange II (OR) azo dye into nontoxic products (gases and weak acids). The Eleocharis@MnPE layered hybrid efficiently degraded both OR in synthetic wastewater and also other azo dyes (red, pink, and yellow dyes) present in three different textile industrial effluents. For the industrial effluents, these were evidenced by the color disappearance and reduction in biological oxygen demand (BOD), chemical oxygen demand (COD), and total organic carbon (TOC) of up to 97%, 92%, and 76%, respectively. Furthermore, reduced toxicity of treated wastewater was confirmed by decreased cell toxicity to 0.1%-1% and increased cell viability to 90%. We believe that designing a hybrid system with strong ability of SACB could be highly effective for industrial-scale treatment of wastewater

Predictors of short-term mortality in patients undergoing percutaneous dilatational tracheostomy

Purpose: The purpose of the study was to identify the predictors of short-term mortality in patients undergoing percutaneous dilatational tracheostomy (PDT). Materials and methods: Retrospective analysis of data pertaining to adult patients who underwent PDT between July 2005 and June 2008 in an urban, academic, tertiary care medical center was done. Clinical and demographic data were analyzed for 483 patients undergoing PDT via multivariate logistic regression. Results: Mortality data were examined at in-hospital, 14, 30, and 180 days postprocedure. Overall mortality rates were 11% at 14 days, 19% at 30 days, and 40% at 180 days. In-hospital mortality was 30%. Conclusions: Patients undergoing PDT have significant short-term mortality with 11% dying within 14 days and an in-hospital mortality rate of 30%. We identified an index diagnosis of ventilator-associated pneumonia and trauma to be associated with a higher survival rate, whereas older age, oncological diagnosis, cardiogenic shock, and ventricular-assist devices were associated with higher mortality. There is significant heterogeneity in both underlying diagnosis and patient outcomes, and these factors should be considered when deciding to perform this procedure and discussed with patients/family members to provide a realistic expectation of potential prognosi

Predictors of short-term mortality in patients undergoing percutaneous dilatational tracheostomy

PURPOSE: The purpose of the study was to identify the predictors of short-term mortality in patients undergoing percutaneous dilatational tracheostomy (PDT). MATERIALS AND METHODS: Retrospective analysis of data pertaining to adult patients who underwent PDT between July 2005 and June 2008 in an urban, academic, tertiary care medical center was done. Clinical and demographic data were analyzed for 483 patients undergoing PDT via multivariate logistic regression. RESULTS: Mortality data were examined at in-hospital, 14, 30, and 180 days postprocedure. Overall mortality rates were 11% at 14 days, 19% at 30 days, and 40% at 180 days. In-hospital mortality was 30%. CONCLUSIONS: Patients undergoing PDT have significant short-term mortality with 11% dying within 14 days and an in-hospital mortality rate of 30%. We identified an index diagnosis of ventilator-associated pneumonia and trauma to be associated with a higher survival rate, whereas older age, oncological diagnosis, cardiogenic shock, and ventricular-assist devices were associated with higher mortality. There is significant heterogeneity in both underlying diagnosis and patient outcomes, and these factors should be considered when deciding to perform this procedure and discussed with patients/family members to provide a realistic expectation of potential prognosis